Commercialising a unique cardiac screening technology
Oxentia worked with a Ukrainian technology institute to commercialise a unique, non-invasive cardiac screening technology, a first level diagnostic tool for initial evaluation of patients at risk for cardiac disease or defects. Oxentia helped the team of researchers secure IP rights, complete a market research and a feasibility study, and prepare a business plan. Oxentia helped Cardiomox raise £2 million in order to start up. The company is now preparing for CE marking in the UK and its Chinese partner is preparing for approval from the China Food and Drug Administration.